Open Access

Auranofin induces urothelial carcinoma cell death via
reactive oxygen species production and synergy with cisplatin

  • Authors:
    • San-Yuan Chen
    • Chun-Nun Chao
    • Hsin-Yi Huang
    • Chiung-Yao Fang
  • View Affiliations

  • Published online on: December 27, 2021     https://doi.org/10.3892/ol.2021.13179
  • Article Number: 61
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Urothelial carcinoma (UC) is one of the most common cancer types of the urinary tract. UC is associated with poor 5‑year survival rate, and resistance to cisplatin‑based therapy remains a challenge for invasive bladder cancer treatment. Therefore, there is an urgent need to develop new drugs for advanced UC therapy. Auranofin (AF) was developed over 30 years ago for the treatment of rheumatoid arthritis and has been reported to exert an antitumor effect by increasing the level of reactive oxygen species (ROS) in cancer cells. The aim of the present study was to examine the effects of AF on cancer cell proliferation, cell cycle and apoptosis, either alone or in combination with cisplatin. AF induced cell death in two separate cell lines, HT 1376 and BFTC 909, in a concentration‑ and time‑dependent manner by inducing cell cycle arrest. However, the distribution of cells in different phases of the cell cycle differed between the two cell lines, with G0/G1 cell cycle arrest in HT 1376 cells and S phase arrest in BFTC 909 cells. In addition, AF induced apoptosis in HT 1376, as well as redox imbalance in both HT 1376 and BFTC 909 cells. Cell viability was rescued following treatment with N‑acetyl‑L‑cysteine, a ROS scavenger. Furthermore, AF treatment synergistically increased the cytotoxicity of HT 1376 and BFTC 909 cells when combined with cisplatin treatment. These findings suggest that AF may represent a potential candidate drug against UC and increase the therapeutic effect of cisplatin.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen S, Chao C, Huang H and Fang C: Auranofin induces urothelial carcinoma cell death via <br />reactive oxygen species production and synergy with cisplatin. Oncol Lett 23: 61, 2022
APA
Chen, S., Chao, C., Huang, H., & Fang, C. (2022). Auranofin induces urothelial carcinoma cell death via <br />reactive oxygen species production and synergy with cisplatin. Oncology Letters, 23, 61. https://doi.org/10.3892/ol.2021.13179
MLA
Chen, S., Chao, C., Huang, H., Fang, C."Auranofin induces urothelial carcinoma cell death via <br />reactive oxygen species production and synergy with cisplatin". Oncology Letters 23.2 (2022): 61.
Chicago
Chen, S., Chao, C., Huang, H., Fang, C."Auranofin induces urothelial carcinoma cell death via <br />reactive oxygen species production and synergy with cisplatin". Oncology Letters 23, no. 2 (2022): 61. https://doi.org/10.3892/ol.2021.13179